Teva To Invest Billion In India Acquisitions, New Facility
This article was originally published in PharmAsia News
Executive Summary
Teva Pharmaceutical Industries of Israel says it plans to spend more than $1 billion in India, about three-fourths of the amount in buying Indian drug makers. The company said it expects to spend $250 million to $300 million on building manufacturing facilities in India, mainly for active pharmaceutical ingredient work. Teva already is the world's largest producer of generic drugs and launched Teva India as its India-based research and development center two years ago. Teva is reported to have been eyeing a major acquisition in India for several years, and possible targets include Aurobindo, Cipla, Matrix, Orchid and Saraca Laboratories. (Click here for more
You may also be interested in...
Teva To Expand Presence In India
LUCKNOW, UTTAR PRADESH, INDIA - Israeli pharmaceutical company Teva Pharmaceutical will invest more than $1 billion in India over the next two years to establish greenfield manufacturing facilities and acquire Indian drug companies, said a Jan. 10 report in the local newspaper Business Standard.
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.